<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Thorac Med</journal-id><journal-id journal-id-type="publisher-id">ATM</journal-id><journal-title-group><journal-title>Annals of Thoracic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1817-1737</issn><issn pub-type="epub">1998-3557</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20835310</article-id><article-id pub-id-type="pmc">2930654</article-id><article-id pub-id-type="publisher-id">ATM-5-153</article-id><article-id pub-id-type="doi">10.4103/1817-1737.65047</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ibrahim</surname><given-names>Ezzeldin M.</given-names></name><xref ref-type="aff" rid="AF0001"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="AF0001">Oncology Center of Excellence, International Medical Center, Jeddah, Saudi Arabia</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Ezzeldin M. Ibrahim, Professor of Medicine and Oncology, Chairman, Oncology Center of Excellence, Executive Director, Research Center, International Medical Center, P.O. Box 2172, Jeddah 21451, Saudi Arabia E-mail: <email xlink:href="ezzibrahim@imc.med.sa">ezzibrahim@imc.med.sa</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2010</year></pub-date><volume>5</volume><issue>3</issue><fpage>153</fpage><lpage>160</lpage><history><date date-type="rev-recd"><day>22</day><month>4</month><year>2010</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2010</year></date></history><permissions><copyright-statement>&#x000a9; Annals of Thoracic Medicine</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>OBJECTIVE:</title><p>Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have failed to demonstrate such benefit. It was later reported that gefitinib had a positive outcome when used in selected population.</p></sec><sec id="st2"><title>RATIONAL:</title><p>The inconsistent results and the lack published meta-analysis that systematically examined the overall efficacy of gefitinib in the frontline setting in such patients, have prompted the current meta-analysis.</p></sec><sec id="st3"><title>METHODS:</title><p>We selected for analysis only those randomized, peer-reviewed clinical studies where the efficacy of gefitinib-based therapy (GBT) was investigated in chemotherapy na&#x000ef;ve patients with locally advanced or metastatic NSCLC. We also included studies where patients were randomized between gefitinib vs. placebo or none after initial chemoradiation or chemotherapy induction offered to all included patients.</p></sec><sec id="st4"><title>RESULTS:</title><p>We identified seven eligible studies involving 2,646 and 1,939 patients randomized to GBT and to control arms, respectively. In mostly unselected population, GBT was not associated with higher objective response rate (ORR), progression-free survival (PFS) (hazard ratio [HR] = 0.97, 95% CI: 0.78&#x02013;1.20, <italic>P</italic> = 0.78), or overall survival (OS) (HR = 1.04, 95% CI: 0.95&#x02013;1.13, <italic>P</italic> = 0.45) as compared with control interventions. In a fraction of patients with known EGFR mutation status, GBT showed significantly higher ORR among patients with mutant EGFR (odds ratio [OR] = 2.81, 95% CI: 1.71&#x02013;4.62, <italic>P</italic> &#x0003c; 0.0001); however, EGFR mutation was not associated with better PFS or OS with GBT. Nevertheless, patients receiving GBT experienced significant improvement in quality of life as compared with those in the control arms.</p></sec><sec id="st5"><title>CONCLUSION:</title><p>We conclude that GBT cannot be recommended for frontline management of patients with advanced NSCLC in unselected patient population.</p></sec></abstract><kwd-group><kwd>EGFR</kwd><kwd>gefitinib</kwd><kwd>non-small cell lung cancer</kwd></kwd-group></article-meta></front><body><p>Lung cancer remains the highest cause of cancer-related mortality. In patients with locally advanced and metastatic non-small cell lung cancer (NSCLC), short-lived responses to aggressive chemotherapy are observed in approximately 30% of patients, the impact on patient survival has been modest.[<xref ref-type="bibr" rid="CIT1">1</xref>]</p><p>The small molecule tyrosine kinase inhibitor (TKI), gefitinib (Iressa; AstraZeneca, Wilmington, DE), targets the epidermal growth factor receptor (EGFR) was tested in chemotherapy-refractory NSCLC patients, on the basis of their frequent expression of EGFR and their poor response to standard therapies. In two large phase II trials (the Iressa Dose Evaluation in Advanced Lung Cancer [IDEAL] 1 study and the IDEAL 2 study), the results indicated that gefitinib had a substantial effect as a salvage treatment for patients who had failed at least one or two previous regimens of chemotherapy.[<xref ref-type="bibr" rid="CIT2">2</xref><xref ref-type="bibr" rid="CIT3">3</xref>]</p><p>Two subsequent phase III trials randomized previously untreated patients with advanced NSCLC to standard platinum-based chemotherapy, with or without the addition of gefitinib at two doses.[<xref ref-type="bibr" rid="CIT4">4</xref><xref ref-type="bibr" rid="CIT5">5</xref>] These trials reported no difference in objective response rate (ORR), progression-free survival (PFS), or overall survival (OS) with the addition of gefitinib to standard chemotherapy.</p><p>While initial trials of gefitinib failed to show activity in most cases of NSCLC, a subset of cases that did respond had rapid and dramatic tumor shrinkage. These responses were more common in women, East Asians, and nonsmokers, and their tumors were primarily adenocarcinomas. It was later reported that the majority of tumors with dramatic responses harbor mutations in the EGFR kinase domain that were not found in nonresponsive cases.[<xref ref-type="bibr" rid="CIT6">6</xref>&#x02013;<xref ref-type="bibr" rid="CIT8">8</xref>] Moreover, other phase III studies have reported positive outcome when gefitinib was used in selected population.[<xref ref-type="bibr" rid="CIT9">9</xref>]</p><p>The inconsistent results, the intriguing role of EGFR mutations, the influence of patients selection, and the lack published meta-analysis that systematically examined the overall efficacy of gefitinib in the frontline setting in patients with locally advanced or metastatic NSCLC, have prompted the current meta-analysis that intended to examine the potential benefit of gefitinib in that setting.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><sec id="sec2-1"><title>Literature search</title><p>We did a comprehensive search of citations from PubMed, proceedings of the main oncology conferences, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Database of Abstracts of Review of Effectiveness. The search was limited to randomized, peer-reviewed clinical studies and reviews in English language. Our initial search through each resource used queries with the medical subject headings (MeSH) terms: &#x0201c;lung neoplasm&#x0201d;, OR &#x0201c;lung cancer&#x0201d; AND &#x0201c;gefitinib&#x0201d;. The search strategy also used several text terms to identify relevant information. Reference lists from relevant primary studies and review articles were examined to find other additional publications.</p></sec><sec id="sec2-2"><title>Study selection</title><p>We selected for analysis only those randomized, peer-reviewed clinical studies where the efficacy of gefitinib-based therapy (GBT) was investigated in chemotherapy na&#x000ef;ve patients with locally advanced or metastatic NSCLC. We also included studies where patients were randomized between gefitinib vs. placebo or none after initial chemoradiation or chemotherapy induction offered to all included patients.</p></sec><sec id="sec2-3"><title>Statistical methods</title><p>Before performing the analyses, data of each study were carefully checked and verified for coherence with the original publications. Data were entered in a computer database for transfer and statistical analysis in Review Manager Version 5.0.17 (Cochrane Collaboration, Software Update, Oxford, UK) and Comprehensive Meta Analysis Version 2.2.048 (NJ, USA). For trials included in this meta-analysis, if log hazard ratio (HR) and its variance were not presented explicitly, appropriate estimations methods were used to extract estimates of these statistics.[<xref ref-type="bibr" rid="CIT10">10</xref><xref ref-type="bibr" rid="CIT11">11</xref>]</p><p>In this meta-analysis, both fixed and random effect models were tested where appropriate.[<xref ref-type="bibr" rid="CIT12">12</xref><xref ref-type="bibr" rid="CIT13">13</xref>] <italic>X</italic><sup>2</sup> tests were used to study heterogeneity between trials. <italic>I</italic><sup>2</sup> statistic was used to estimate the percentage of total variation across studies, due to heterogeneity rather than chance. If the <italic>P</italic> value was &#x02264;0.1, the assumption of homogeneity was deemed invalid, and the random-effects model was reported after exploring the causes of heterogeneity.[<xref ref-type="bibr" rid="CIT14">14</xref>] A two-tailed <italic>P</italic> value of &#x0003c;0.05 was considered statistically significant. Publication bias was explored through visual inspection of the funnel plots.[<xref ref-type="bibr" rid="CIT13">13</xref>] Findings of the meta-analysis are depicted in classical Forest plots, with point estimates and 95% confidence interval (CI) for each trial and overall; size of the squares is proportional to effect size.</p></sec></sec><sec id="sec1-2"><title>Results</title><sec id="sec2-4"><title>Studies and patient characteristics</title><p>After exclusion of duplicate and irrelevant studies, our search yielded seven eligible published studies that were retrieved for evaluation that is more detailed. There were 2,646 and 1,939 patients randomized to GBT and to the control arms, respectively. Of the included studies, four studies compared gefitinib plus chemotherapy vs. chemotherapy alone,[<xref ref-type="bibr" rid="CIT5">5</xref><xref ref-type="bibr" rid="CIT15">15</xref>&#x02013;<xref ref-type="bibr" rid="CIT17">17</xref>] two studies compared gefitinib alone vs. chemotherapy,[<xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT18">18</xref>] and one study compared gefitinib plus best supportive care (BSC) vs. BSC alone.[<xref ref-type="bibr" rid="CIT19">19</xref>] Analysis of the efficacy of gefitinib in the Iressa NSCLC Trial Assessing Combination Treatment (INTACT-1)[<xref ref-type="bibr" rid="CIT15">15</xref>] and INTACT-2[<xref ref-type="bibr" rid="CIT5">5</xref>] studies based on EGFR expression, mutations, and gene amplification were also included.[<xref ref-type="bibr" rid="CIT6">6</xref>] <xref ref-type="table" rid="T0001">Table 1</xref> depicts the main characteristics of the included studies, whereas <xref ref-type="table" rid="T0002">Table 2</xref> shows the summary of the efficacy data.</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Characteristics of the seven studies included in the meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Description and patient selection</th><th align="center" colspan="15" rowspan="1">Gefitinib-based therapy/control<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">No.</th><th align="center" valign="top" rowspan="1" colspan="1">Median age</th><th align="center" valign="top" rowspan="1" colspan="1">Male %</th><th align="center" colspan="2" rowspan="1">Stage %<hr/></th><th align="center" colspan="1" valign="top" rowspan="1">Histology<hr/></th><th align="center" colspan="3" valign="top" rowspan="1">Performance status<hr/></th><th align="center" colspan="4" valign="top" rowspan="1">Race<hr/></th><th align="center" colspan="2" valign="top" rowspan="1">Smoking<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">IIIB</th><th align="center" rowspan="1" colspan="1">IV</th><th align="center" rowspan="1" colspan="1">AC%</th><th align="center" rowspan="1" colspan="1">PS 0</th><th align="center" rowspan="1" colspan="1">PS 1</th><th align="center" rowspan="1" colspan="1">PS 2</th><th align="center" rowspan="1" colspan="1">White</th><th align="center" rowspan="1" colspan="1">Asian</th><th align="center" rowspan="1" colspan="1">Black</th><th align="center" rowspan="1" colspan="1">Other</th><th align="center" rowspan="1" colspan="1">Ever</th><th align="center" rowspan="1" colspan="1">Never</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Giaccone 2004[<xref ref-type="bibr" rid="CIT15">15</xref>]</td><td align="left" rowspan="1" colspan="1">Phase III randomized, double-blind, placebo-controlled (INTACT-1): Gemcitabine + cisplatin + gefitinib 500 mg vs. gemcitabine + cisplatin + gefitinib 250 mg vs. gemcitabine + cisplatin + placebo Unselected patients.</td><td align="center" rowspan="1" colspan="1">365/365/363</td><td align="center" rowspan="1" colspan="1">61/59/61</td><td align="center" rowspan="1" colspan="1">72/77/72</td><td align="center" rowspan="1" colspan="1">30/26/28</td><td align="center" rowspan="1" colspan="1">67/72/69</td><td align="center" rowspan="1" colspan="1">43/49/47</td><td align="center" rowspan="1" colspan="1">32/34/34</td><td align="center" rowspan="1" colspan="1">58/56/56</td><td align="center" rowspan="1" colspan="1">10/10/10</td><td align="center" rowspan="1" colspan="1">91/90/90</td><td align="center" rowspan="1" colspan="1">2/2/1</td><td align="center" rowspan="1" colspan="1">8/4/5</td><td align="center" rowspan="1" colspan="1">8/4/5</td><td align="center" rowspan="1" colspan="1">NR 32/32</td><td align="center" rowspan="1" colspan="1">NR 32/32</td></tr><tr><td align="left" rowspan="1" colspan="1">Herbst <italic>et al</italic>. 2004[<xref ref-type="bibr" rid="CIT5">5</xref>]</td><td align="left" rowspan="1" colspan="1">Phase III randomized, double-blind, placebo-controlled (INTACT-2). Paclitaxel + carboplatin + gefitinib 500 mg vs. paclitaxel + carboplatin + gefitinib 250 mg vs. paclitaxel + carboplatin + placebo Unselected patients.</td><td align="center" rowspan="1" colspan="1">347/345</td><td align="center" rowspan="1" colspan="1">62/61/63</td><td align="center" rowspan="1" colspan="1">40/42/39</td><td align="center" rowspan="1" colspan="1">15/16/17</td><td align="center" rowspan="1" colspan="1">82/81/78</td><td align="center" rowspan="1" colspan="1">58/56/52</td><td align="center" rowspan="1" colspan="1">35/33/39</td><td align="center" rowspan="1" colspan="1">52/57/52</td><td align="center" rowspan="1" colspan="1">13/10/9</td><td align="center" rowspan="1" colspan="1">89/90/92</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8/4/5</td><td align="center" rowspan="1" colspan="1">4/6/3</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Kelly <italic>et al</italic>. 2008[<xref ref-type="bibr" rid="CIT17">17</xref>]</td><td align="left" rowspan="1" colspan="1">Phase III randomized, placebo-controlled. Concurrent radiotherapy and etoposide- cisplatin followed by docetaxel. then randomization to gefitinib vs. placebo. Patients with Stage III and PS 0 or 1, no plural or pericardial effusion.</td><td align="center" rowspan="1" colspan="1">118/125</td><td align="center" rowspan="1" colspan="1">62/61</td><td align="center" rowspan="1" colspan="1">79/74</td><td align="center" rowspan="1" colspan="1">IIIA 45/51 IIIB 55/49</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">30/33</td><td align="center" rowspan="1" colspan="1">51/56</td><td align="center" rowspan="1" colspan="1">45/40</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">97/86</td><td align="center" rowspan="1" colspan="1">0/2</td><td align="center" rowspan="1" colspan="1">3/11</td><td align="center" rowspan="1" colspan="1">0/2</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" rowspan="1" colspan="1">Takeda <italic>et al</italic>. 2010[<xref ref-type="bibr" rid="CIT16">16</xref>]</td><td align="left" rowspan="1" colspan="1">Phase III randomized, open-label. Platinum-doublet chemotherapy followed by gefitinib vs. platinum-doublet chemotherapy followed by platinum-doublet chemotherapy. All Japanese patients.</td><td align="center" rowspan="1" colspan="1">300/298</td><td align="center" rowspan="1" colspan="1">62/63</td><td align="center" rowspan="1" colspan="1">64/64</td><td align="center" rowspan="1" colspan="1">18/18</td><td align="center" rowspan="1" colspan="1">82/82</td><td align="center" rowspan="1" colspan="1">79/78</td><td align="center" rowspan="1" colspan="1">30/35</td><td align="center" rowspan="1" colspan="1">70/65</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100/100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">67/70</td><td align="center" rowspan="1" colspan="1">32/30</td></tr><tr><td align="left" rowspan="1" colspan="1">Crino <italic>et al</italic>. 2008[<xref ref-type="bibr" rid="CIT18">18</xref>]</td><td align="left" rowspan="1" colspan="1">Phase II, randomized, open-label (INVITE). Gefitinib vs. vinorelbine. Patients &#x02265; 70 years of age.</td><td align="center" rowspan="1" colspan="1">97/99</td><td align="center" rowspan="1" colspan="1">74/74</td><td align="center" rowspan="1" colspan="1">77/74</td><td align="center" rowspan="1" colspan="1">20/26</td><td align="center" rowspan="1" colspan="1">80/74</td><td align="center" rowspan="1" colspan="1">35/45</td><td align="center" rowspan="1" colspan="1">13/21</td><td align="center" rowspan="1" colspan="1">63/62</td><td align="center" rowspan="1" colspan="1">24/16</td><td align="center" rowspan="1" colspan="1">81/84</td><td align="center" rowspan="1" colspan="1">18/14</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1/2</td><td align="center" rowspan="1" colspan="1">82/89</td><td align="center" rowspan="1" colspan="1">18/11</td></tr><tr><td align="left" rowspan="1" colspan="1">Mok <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT9">9</xref>]</td><td align="left" rowspan="1" colspan="1">Phase III randomized, open-label. Gefitinib vs. paclitaxel- carboplatin. Patients non- or former light-smoker, East Asian, with AC.</td><td align="center" rowspan="1" colspan="1">609/</td><td align="center" rowspan="1" colspan="1">57/57</td><td align="center" rowspan="1" colspan="1">21/21</td><td align="center" rowspan="1" colspan="1">25/24</td><td align="center" rowspan="1" colspan="1">75/76</td><td align="center" rowspan="1" colspan="1">100/100</td><td align="center" rowspan="1" colspan="1">26/26</td><td align="center" rowspan="1" colspan="1">64/63</td><td align="center" rowspan="1" colspan="1">10/11</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100/100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6/6</td><td align="center" rowspan="1" colspan="1">94/94</td></tr><tr><td align="left" rowspan="1" colspan="1">Goss <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT19">19</xref>]</td><td align="left" rowspan="1" colspan="1">Phase II randomized, placebo-controlled. Gefitinib-BSC vs. BSC only. Patients with WHO PS 2-3.</td><td align="center" rowspan="1" colspan="1">100/101</td><td align="center" rowspan="1" colspan="1">74/76</td><td align="center" rowspan="1" colspan="1">61/60</td><td align="center" rowspan="1" colspan="1">16/17</td><td align="center" rowspan="1" colspan="1">84/83</td><td align="center" rowspan="1" colspan="1">45/46</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">PS 2 55/62 PS3 45/38</td><td align="center" rowspan="1" colspan="1">96/96</td><td align="center" rowspan="1" colspan="1">4/3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">90/91</td><td align="center" rowspan="1" colspan="1">10/9</td></tr></tbody></table><table-wrap-foot><fn><p>AC, Adenocarcinoma; PS, performance status; NR, not reported.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Summary of the efficacy analysis of the seven studies included in the meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Primary end point</th><th align="center" rowspan="1" colspan="1">Median FU (ms)</th><th align="center" colspan="3" rowspan="1">ORR%<hr/></th><th align="center" colspan="3" rowspan="1">PFS (months)<hr/></th><th align="center" colspan="3" rowspan="1">OS (months)<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">GBT</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">GBT</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">GBT</th><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Giaccone 2004[<xref ref-type="bibr" rid="CIT15">15</xref>]</td><td align="center" rowspan="1" colspan="1">OS</td><td align="center" rowspan="1" colspan="1">15.9</td><td align="center" rowspan="1" colspan="1">50<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">5.5<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">6.0</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">9.9<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">10.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Herbst <italic>et al</italic>. 2004[<xref ref-type="bibr" rid="CIT5">5</xref>]</td><td align="center" rowspan="1" colspan="1">OS</td><td align="center" rowspan="1" colspan="1">6.0 (PFS)</td><td align="center" rowspan="1" colspan="1">30<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">4.6<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">5.0</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">8.7<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1">9.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12.0 (OS)</td><td align="center" rowspan="1" colspan="1">30<xref ref-type="table-fn" rid="T000F2">+</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">5.3<xref ref-type="table-fn" rid="T000F2">+</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9.8<xref ref-type="table-fn" rid="T000F1">*</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Kelly <italic>et al</italic>. 2008[<xref ref-type="bibr" rid="CIT17">17</xref>]</td><td align="center" rowspan="1" colspan="1">OS</td><td align="center" rowspan="1" colspan="1">27.0 (pre-mature closure)</td><td align="center" rowspan="1" colspan="1">Not applicable</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8.3</td><td align="center" rowspan="1" colspan="1">11.7</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">23.0</td><td align="center" rowspan="1" colspan="1">35.0</td><td align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">Takeda <italic>et al</italic>. 2010[<xref ref-type="bibr" rid="CIT16">16</xref>]</td><td align="center" rowspan="1" colspan="1">OS</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">4.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">13.7</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Crino <italic>et al</italic>. 2008[<xref ref-type="bibr" rid="CIT18">18</xref>]</td><td align="center" rowspan="1" colspan="1">PFS</td><td align="center" rowspan="1" colspan="1">6.0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">8.0</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Mok <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT9">9</xref>]</td><td align="center" rowspan="1" colspan="1">PFS</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">5.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">18.7</td><td align="center" rowspan="1" colspan="1">17.3</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Goss <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT19">19</xref>]</td><td align="center" rowspan="1" colspan="1">PFS</td><td align="center" rowspan="1" colspan="1">1.3 (PFS)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">~3.0 (OS)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>NS, Not significant; OS, overall survival; PFS, progression-free survival</p></fn><fn id="T000F1"><label>*</label><p>Gefitinib 500 mg</p></fn><fn id="T000F2"><label>+</label><p>gefitinib 250 mg</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-5"><title>Objective response rate</title><p>There was significant heterogeneity between studies (<italic>P</italic> = 0.02); therefore, the random effects model was examined. <xref ref-type="fig" rid="F0001">Figure 1</xref> shows that in none of the comparisons was the ORR significantly different in the GBT vs. the control interventions. Of the original INTACT-1[<xref ref-type="bibr" rid="CIT15">15</xref>] and INTACT-2[<xref ref-type="bibr" rid="CIT5">5</xref>] trials, molecular analysis for EGFR mutation status was known in 150 patients (7%),[<xref ref-type="bibr" rid="CIT6">6</xref>] whereas the status was known in 437 patients (36%) of the study of Mok <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT9">9</xref>] <xref ref-type="fig" rid="F0002">Figure 2</xref> shows that GBT was associated with almost threefold higher ORR compared with the control regimens among patients with positive EGFR mutation (OR = 2.81, 95% CI: 1.71&#x02013;4.62, <italic>P</italic> &#x0003c; 0.0001). On the other hand, no benefit was demonstrated among mutation-negative patients. The positive effect in mutation-positive patients was mainly attributed to the outcome of the Mok <italic>et al</italic>. trial that included select population [<xref ref-type="table" rid="T0001">Table 1</xref>].[<xref ref-type="bibr" rid="CIT9">9</xref>]</p><fig id="F0001" position="float"><label>Figure 1</label><caption><p>Odds ratio of objective response rate of GBT vs. control interventions (random effects model). G, Gefitinib</p></caption><graphic xlink:href="ATM-5-153-g001"/></fig><fig id="F0002" position="float"><label>Figure 2</label><caption><p>Odds ratio of objective response rate of GBT vs. control interventions according to EGFR mutation status (random effects model). G, Gefitinib</p></caption><graphic xlink:href="ATM-5-153-g002"/></fig></sec><sec id="sec2-6"><title>Progression-free survival</title><p>Analysis of PFS using the random effects model [<xref ref-type="fig" rid="F0003">Figure 3</xref>], failed to show any significant benefit of GBT vs. control regardless of trials designs (HR = 0.97, 95% CI: 0.78&#x02013;1.20, <italic>P</italic> = 0.78), neither was any PFS advantage was found among patients with mutant or wild EGFR [<xref ref-type="table" rid="T0003">Table 3</xref>].</p><fig id="F0003" position="float"><label>Figure 3</label><caption><p>The hazard ratio for progression-free survival of GBT vs. control interventions (random effects model). G; Gefitinib</p></caption><graphic xlink:href="ATM-5-153-g003"/></fig><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Efficacy of Gefitinib-based therapy vs. control according to EGFR mutation status and histology</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">PFS<hr/></th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">OS<hr/></th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>EGFR mutant</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bell <italic>et al</italic>. 2005[<xref ref-type="bibr" rid="CIT6">6</xref>]</td><td align="center" rowspan="1" colspan="1">0.55 (0.19&#x02013;1.60)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Bell <italic>et al</italic>. 2005[<xref ref-type="bibr" rid="CIT6">6</xref>]</td><td align="center" rowspan="1" colspan="1">1.77 (0.50&#x02013;6.25)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Crino <italic>et al</italic>. 2008[<xref ref-type="bibr" rid="CIT18">18</xref>]</td><td align="center" rowspan="1" colspan="1">3.13 (1.45&#x02013;6.76)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Crino 2008[<xref ref-type="bibr" rid="CIT18">18</xref>]</td><td align="center" rowspan="1" colspan="1">2.88 (1.21&#x02013;6.85)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Goss <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT19">19</xref>]</td><td align="center" rowspan="1" colspan="1">0.29 (0.11&#x02013;0.75)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Goss <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT19">19</xref>]</td><td align="center" rowspan="1" colspan="1">0.44 (0.17&#x02013;1.13)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mok <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT9">9</xref>]</td><td align="center" rowspan="1" colspan="1">0.48 (0.36&#x02013;0.64)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mok <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT9">9</xref>]</td><td align="center" rowspan="1" colspan="1">0.78 (0.49&#x02013;1.23)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">0.71 (0.27&#x02013;1.85)</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.10 (0.51&#x02013;2.40)</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">EGFR wild</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bell <italic>et al</italic>. 2005[<xref ref-type="bibr" rid="CIT6">6</xref>]</td><td align="center" rowspan="1" colspan="1">0.73 (0.53&#x02013;1.01)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Bell <italic>et al</italic>. 2005[<xref ref-type="bibr" rid="CIT6">6</xref>]</td><td align="center" rowspan="1" colspan="1">0.91 (0.76&#x02013;1.23)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Goss <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT19">19</xref>]</td><td align="center" rowspan="1" colspan="1">0.74 (0.38&#x02013;1.45)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Goss <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT19">19</xref>]</td><td align="center" rowspan="1" colspan="1">1.02 (0.56&#x02013;1.87)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mok <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT9">9</xref>]</td><td align="center" rowspan="1" colspan="1">2.85 (2.05&#x02013;3.97)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mok <italic>et al</italic>. 2009[<xref ref-type="bibr" rid="CIT9">9</xref>]</td><td align="center" rowspan="1" colspan="1">1.38 (0.92&#x02013;2.08)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1">1.17 (0.43&#x02013;3.19)</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.06 (0.81&#x02013;1.39)</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">0.89 (0.45&#x02013;1.76)</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.06 (0.77&#x02013;1.47)</td><td align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Adenocarcinoma</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Herbst <italic>et al</italic>. 2004[<xref ref-type="bibr" rid="CIT5">5</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">500 mg</td><td align="center" rowspan="1" colspan="1">1.03 (0.81&#x02013;1.31)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">250 mg</td><td align="center" rowspan="1" colspan="1">1.16 (0.90&#x02013;1.48)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Takeda <italic>et al</italic>. 2010[<xref ref-type="bibr" rid="CIT16">16</xref>]</td><td align="center" rowspan="1" colspan="1">0.79 (0.64&#x02013;0.97)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.97 (0.77&#x02013;1.22)</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Non-adenocarcinoma</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Herbst <italic>et al</italic>. 2004[<xref ref-type="bibr" rid="CIT5">5</xref>]</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">500 mg</td><td align="center" rowspan="1" colspan="1">0.74 (0.52&#x02013;1.04)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">250 mg</td><td align="center" rowspan="1" colspan="1">0.92 (0.64&#x02013;1.32)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Takeda <italic>et al</italic>. 2010[<xref ref-type="bibr" rid="CIT16">16</xref>]</td><td align="center" rowspan="1" colspan="1">1.24 (0.85&#x02013;1.80)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Subtotal</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.94 (0.70&#x02013;1.26)</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.96 (0.81&#x02013;1.13)</td><td align="center" rowspan="1" colspan="1">0.60</td></tr></tbody></table></table-wrap></sec><sec id="sec2-7"><title>Overall survival</title><p>Similar to the outcome of PFS analysis, using the random effects model, could not demonstrate significant OS advantage of GBT vs. control in the different trials designs [<xref ref-type="fig" rid="F0004">Figure 4</xref>]; HR = 1.04 (95% CI: 0.95&#x02013;1.13, <italic>P</italic> = 0.45). Statistically significant OS survival for GBT was not demonstrated regardless of tumor histology (adenocarcinoma vs. non-adenocarcinoma), or EGFR mutation status [<xref ref-type="table" rid="T0003">Table 3</xref>].</p><fig id="F0004" position="float"><label>Figure 4</label><caption><p>The hazard ratio for overall survival of GBT vs. control interventions (random effects model). G, Gefitinib</p></caption><graphic xlink:href="ATM-5-153-g004"/></fig></sec><sec id="sec2-8"><title>Analysis of PFS and OS according to other prognostic features</title><p>There were no adequate reported data to allow analysis of PFS according to race, age, gender, or histology. Neither were adequate data for analyzing OS according to race, age, or gender. Combining the data of the studies of Mok <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT9">9</xref>] and Takeda <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT16">16</xref>] that included only Asian population showed that there was a significant PFS benefit from GBT vs. non-gefitinib interventions (HR = 0.72, 95% CI: 0.65&#x02013;0.08, P &#x0003c; 0.0001); however, the difference in ORR was not different (HR = 1.15, 95% CI: 0.59&#x02013;2.22, <italic>P</italic> = 0.69). OS analysis was not possible as there were no enough survival data reported from the study of Takeda <italic>et al</italic>.[<xref ref-type="bibr" rid="CIT16">16</xref>]</p></sec><sec id="sec2-9"><title>Quality of life</title><p>In three studies,[<xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT18">18</xref><xref ref-type="bibr" rid="CIT19">19</xref>] there were adequate reported data that allowed analysis of the effect of GBT on the QOL. QOL was assessed with the use of the Functional Assessment of Cancer Therapy&#x02013;Lung (FACT-L) questionnaire, and the Trial Outcome Index (TOI), which is the sum of the physical well-being, functional well-being, and the lung-cancer subscale (LCS) scores of FACT-L. <xref ref-type="fig" rid="F0005">Figure 5</xref> shows that significantly more patients in the GBT than in the control had an improvement in QOL as assessed by scores on the FACT-L questionnaire (OR = 1.38; 95% CI: 1.06&#x02013;1.79; <italic>P</italic> = 0.02) and by scores on the TOI (OR = 1.87; 95% CI: 1.13&#x02013;3.09; <italic>P</italic> = 0.02). However, rates of reduction in symptoms, as assessed on the basis of the LCS scores, were similar in patients who received GBT and those randomized to the control groups (OR = 1.14; 95% CI: 0.92&#x02013;1.42; <italic>P</italic> = 0.24).</p><fig id="F0005" position="float"><label>Figure 5</label><caption><p>Odds ratio of quality of life assessment of GBT vs. control interventions (random effects model). FACT-L, Functional Assessment of Cancer Therapy-Lung; G, Gefitinib; LCS, Lung&#x02013;cancer subscale; TOI, Trial outcome index</p></caption><graphic xlink:href="ATM-5-153-g005"/></fig></sec></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>This meta-analysis did not demonstrate improvement in clinical outcomes with the first-line GBT in advanced NSCLC in unselected patient population. Most patients included in these trials probably better reflects the population seen in daily clinical practice, majority of patients were male, smokers, non-Asian, and many had non-adenocarcinoma NSCLC.</p><p>Despite significantly higher ORR achieved with GBT in patients with positive EGFR mutation, that benefit did not lead to PFS or OS advantage in that group. Notably, the ORR gain was mainly attributed to the outcome of the Mok <italic>et al</italic>. trial that only included East Asian patients who were non- or light-smoker and had adenocarcinoma,[<xref ref-type="bibr" rid="CIT9">9</xref>] features that signals a likelihood of clinical benefit from gefitinib. The lack of survival advantage for GBT among those with EGFR mutation could be attributed to the fact that only a fraction of patients had known mutation status. Two hypotheses have been proposed as most likely to explain the negative results of GBT: (1) lack of patient selection for the target, and (2) a negative interaction between EGFR tyrosine kinase inhibitors and chemotherapy when given concurrently.[<xref ref-type="bibr" rid="CIT20">20</xref>]</p><p>In the present meta-analysis, there were insufficient data to allow analysis of PFS or OS according to other prognostic features. Clinical profiles of females, never smokers, adenocarcinoma histology, and Asian ethnicity have all been recognized as favorable subgroups that respond to gefitinib.[<xref ref-type="bibr" rid="CIT21">21</xref>&#x02013;<xref ref-type="bibr" rid="CIT23">23</xref>] Higher EGFR mutation rates are also noted in these subgroups and are also related to a better response to EGFR-TKIs.[<xref ref-type="bibr" rid="CIT7">7</xref><xref ref-type="bibr" rid="CIT24">24</xref>] Nevertheless, the potential gender effect was not demonstrated in the INTACT-2 study.[<xref ref-type="bibr" rid="CIT5">5</xref>] Moreover, in the study of Takeda <italic>et al</italic>.,[<xref ref-type="bibr" rid="CIT16">16</xref>] the benefit of adding gefitinib to platinum-doublet chemotherapy was only shown for smokers, while never-smokers showed no significant benefit. The latter represents a sharp contrast to the benefit shown among never-smoker in the ISEL study.[<xref ref-type="bibr" rid="CIT25">25</xref>]</p><p>On the other hand, as compared with control interventions, GBT showed significant improvement in QOL. For patients with advanced disease, QOL and symptom relief represent important clinical end points, because a definitive cure is not achievable. More patients in the GBT than in the control had an improvement in QOL as assessed by scores on the FACT-L questionnaire and by scores on the TOI. The benefit was demonstrated in the two studies that compared gefitinib vs. chemotherapy,[<xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT18">18</xref>] or in the only study that compared gefitinib against placebo.[<xref ref-type="bibr" rid="CIT19">19</xref>] However, rates of reduction in symptoms, as assessed on the basis of the LCS scores, were similar in patients who received GBT and those randomized to control groups. Nevertheless, the involved cost and the inherent side effects, cannot be justified using gefitinib in that setting to attain some improvement in QOL. In a recent review, Neal <italic>et al</italic>. proposed a strategy is to move these agents to the frontline setting only for select patients.[<xref ref-type="bibr" rid="CIT26">26</xref>]</p><p>We conclude that based on the current meta-analysis, GBT cannot be recommended for the management of patients with advanced NSCLC in the first-line setting as compared with other standard interventions in unselected patient population. The significant improvement in QOL shown with GFT would be offset by the involved cost and the potential side effects known to be associated with the use of gefitinib.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="CIT1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Harrington</surname><given-names>D</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Sandler</surname><given-names>A</given-names></name><name><surname>Krook</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>92</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11784875</pub-id></element-citation></ref><ref id="CIT2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuoka</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>2237</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">12748244</pub-id></element-citation></ref><ref id="CIT3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Natale</surname><given-names>RB</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names><suffix>Jr</suffix></name><name><surname>Prager</surname><given-names>D</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>2149</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">14570950</pub-id></element-citation></ref><ref id="CIT4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name><name><surname>Scagliotti</surname><given-names>G</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><etal/></person-group><article-title>Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 1</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>777</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">14990632</pub-id></element-citation></ref><ref id="CIT5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Natale</surname><given-names>RB</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 2</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>785</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">14990633</pub-id></element-citation></ref><ref id="CIT6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Haserlat</surname><given-names>SM</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8081</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">16204011</pub-id></element-citation></ref><ref id="CIT7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Gurubhagavatula</surname><given-names>S</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><etal/></person-group><article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2129</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">15118073</pub-id></element-citation></ref><ref id="CIT8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><name><surname>Mok</surname><given-names>T</given-names></name><name><surname>Socinski</surname><given-names>MA</given-names></name><name><surname>Gervais</surname><given-names>R</given-names></name><etal/></person-group><article-title>Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>744</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">20038723</pub-id></element-citation></ref><ref id="CIT9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>TS</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Chu</surname><given-names>DT</given-names></name><name><surname>Saijo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>947</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19692680</pub-id></element-citation></ref><ref id="CIT10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmar</surname><given-names>MK</given-names></name><name><surname>Torri</surname><given-names>V</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name></person-group><article-title>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</article-title><source>Stat Med</source><year>1998</year><volume>17</volume><fpage>2815</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9921604</pub-id></element-citation></ref><ref id="CIT11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tierney</surname><given-names>JF</given-names></name><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Ghersi</surname><given-names>D</given-names></name><name><surname>Burdett</surname><given-names>S</given-names></name><name><surname>Sydes</surname><given-names>MR</given-names></name></person-group><article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title><source>Trials</source><year>2007</year><volume>8</volume><fpage>16</fpage><pub-id pub-id-type="pmid">17555582</pub-id></element-citation></ref><ref id="CIT12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><fpage>177</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">3802833</pub-id></element-citation></ref><ref id="CIT13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical test</article-title><source>BMJ</source><year>1997</year><volume>315</volume><fpage>629</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9310563</pub-id></element-citation></ref><ref id="CIT14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name></person-group><article-title>Quantitative synthesis in systematic reviews</article-title><source>Ann Intern Med</source><year>1997</year><volume>127</volume><fpage>820</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9382404</pub-id></element-citation></ref><ref id="CIT15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giaccone</surname><given-names>G</given-names></name></person-group><article-title>The role of gefitinib in lung cancer treatment</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>4233s</fpage><lpage>7s</lpage><pub-id pub-id-type="pmid">15217964</pub-id></element-citation></ref><ref id="CIT16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Hida</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>M</given-names></name><name><surname>Seto</surname><given-names>T</given-names></name><name><surname>Satouchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a west Japan thoracic oncology group trial (WJTOG0203)</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>753</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">20038730</pub-id></element-citation></ref><ref id="CIT17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>K</given-names></name><name><surname>Chansky</surname><given-names>K</given-names></name><name><surname>Gaspar</surname><given-names>LE</given-names></name><name><surname>Albain</surname><given-names>KS</given-names></name><name><surname>Jett</surname><given-names>J</given-names></name><name><surname>Ung</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2450</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18378568</pub-id></element-citation></ref><ref id="CIT18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crino</surname><given-names>L</given-names></name><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Zatloukal</surname><given-names>P</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Pesek</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>4253</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18779612</pub-id></element-citation></ref><ref id="CIT19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname><given-names>G</given-names></name><name><surname>Ferry</surname><given-names>D</given-names></name><name><surname>Wierzbicki</surname><given-names>R</given-names></name><name><surname>Laurie</surname><given-names>SA</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Biesma</surname><given-names>B</given-names></name><etal/></person-group><article-title>Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>2253</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19289623</pub-id></element-citation></ref><ref id="CIT20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandara</surname><given-names>DR</given-names></name><name><surname>Gumerlock</surname><given-names>PH</given-names></name></person-group><article-title>Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out?</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>5856</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16043825</pub-id></element-citation></ref><ref id="CIT21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Seto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>2549</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">16735708</pub-id></element-citation></ref><ref id="CIT22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Endoh</surname><given-names>H</given-names></name><name><surname>Horio</surname><given-names>Y</given-names></name><name><surname>Hida</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2513</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15738541</pub-id></element-citation></ref><ref id="CIT23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SF</given-names></name><name><surname>Liu</surname><given-names>HP</given-names></name><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Ku</surname><given-names>YC</given-names></name><name><surname>Fu</surname><given-names>YN</given-names></name><name><surname>Tsai</surname><given-names>HY</given-names></name><etal/></person-group><article-title>High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>8195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">15623594</pub-id></element-citation></ref><ref id="CIT24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Tracy</surname><given-names>S</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><etal/></person-group><article-title>EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1497</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">15118125</pub-id></element-citation></ref><ref id="CIT25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><name><surname>Rodrigues Pereira</surname><given-names>J</given-names></name><name><surname>Ciuleanu</surname><given-names>T</given-names></name><name><surname>von Pawel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1527</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16257339</pub-id></element-citation></ref><ref id="CIT26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>JW</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name></person-group><article-title>First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations</article-title><source>Clin Adv Hematol Oncol</source><year>2010</year><volume>8</volume><fpage>119</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">20386533</pub-id></element-citation></ref></ref-list></back></article>